Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

Autor: Y. Chai, S. Shacham, E Van Nieuwenhuysen, T.J. Unger, Anne L Kranich, T. Nottrup, Y. Landesman, Mansoor Raza Mirza, Morten Mau-Sørensen, Sileny Han, Charlotte Aaquist Haslund, Bente Lund, M. Kauffman, Ignace Vergote, J. Shah, A. Joshi, Marsha Crochiere, Nicole Concin, Tami Rashal, N. Au, Ulla Peen, Z. Umajuridze

Publikováno v: Vergote, I B, Lund, B, Peen, U, Umajuridze, Z, Mau-Sorensen, M, Kranich, A, Van Nieuwenhuysen, E, Haslund, C, Nottrup, T, Han, S N, Concin, N, Unger, T J, Chai, Y, Au, N, Rashal, T, Joshi, A, Crochiere, M, Landesman, Y, Shah, J, Shacham, S, Kauffman, M & Mirza, M R 2020, ' Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies ', Gynecologic Oncology, vol. 156, no. 2, pp. 308-314 . https://doi.org/10.1016/j.ygyno.2019.11.012

Background Selinexor is an oral inhibitor of the nuclear export protein Exportin 1 (XPO1) with demonstrated antitumor activity in solid and hematological malignancies. We evaluated the efficacy and safety of selinexor in heavily pretreated, recurrent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9ff81ff5dfac1dd3abbd6fdb8002dcb
https://doi.org/10.1016/j.ygyno.2019.11.012